PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway
Open Access
- 1 December 2019
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 10931-10941
Abstract
Introduction: Progression and chemoresistance of acute myeloid leukemia (AML) contribute to most of the treatment failure. Notch pathway has been proven to be involved in many biological processes and diseases, especially AML. In this study, we aimed to explore genes correlated with Notch1 pathway in AML and determine their roles in the regulation of AML progression and chemoresistance. Methods: TCGA database was used to explore Notch1 associated genes. Kaplan–Meier survival analysis was performed to evaluate the prognostic significance of genes. Quantitative RT-PCR (qRT-PCR) and Western blot were performed to examine the expression of genes. The expression of PRKD2 was up-regulated or knocked down in AML cell lines by lentivirus or siRNAs. CCK-8 and flow cytometry were used to analyze the effect of PRKD2 on cell proliferation and chemoresistance. Results: Based on TCGA database, PRKD2 was found to be positively correlated with Notch1 expression, cytogenetic risk status and poorer prognosis in AML. Moreover, the expression level of PRKD2 was higher in AML chemo-resistant cells than in chemo-sensitive cells. Functionally, knockdown of PRKD2-induced apoptosis and increased chemosensitivity of AML cells. PRKD2 overexpression promoted proliferation and chemoresistance of AML cells. Furthermore, we found PRKD2 could regulate Notch1 pathway. Besides, high PRKD2 expression was correlated with higher risk group of AML patients which indicated that PRKD2 was an independent prognostic marker for AML. Conclusion: Taken together, our results showed that PRKD2 could promote the proliferation and chemoresistance of AML cells by regulating Notch1 pathway. The study broadened our insights into the underlying mechanisms in chemoresistance and proliferation of AML, and provided a new prognostic marker and treatment target for AML.Keywords
This publication has 29 references indexed in Scilit:
- The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast CancerCellular Physiology and Biochemistry, 2019
- The Varied Roles of Notch in CancerAnnual Review of Pathology: Mechanisms of Disease, 2017
- Biological and clinical consequences of NPM1 mutations in AMLLeukemia, 2017
- Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.2016
- Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014Clinical Lymphoma Myeloma and Leukemia, 2015
- Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell FrequencyClinical Cancer Research, 2015
- Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in CancerClinical Cancer Research, 2015
- Pediatric AML: From Biology to Clinical ManagementJournal of Clinical Medicine, 2015
- Prognostic impact of δ-like ligand 4 and Notch1 in acute myeloid leukemiaOncology Reports, 2012
- Acquired copy number alterations in adult acute myeloid leukemia genomesProceedings of the National Academy of Sciences, 2009